The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease
Open accessAbstract
MicroRNA-34a (miR-34a) is thought to be involved in nonalcoholic fatty liver disease (NAFLD). However, the association between altered expression of miR-34a and the pathophysiological features of NAFLD remains unclear. Here, we investigated the mechanisms by which miR-34a influences NAFLD through the PPARα-related pathway. Real-time quantitative PCR, western blotting and other assays kit were used to investigate the expression and function of miR-34a in an NAFLD model. Cultured cells transfected with miR-34a inhibitor and C57BL/6 mice injected with the miR-34a inhibitor through vein tail were conducted for the effects of miR-34a on its target. MiR-34a levels were significantly upregulated in steatosis-induced hepatocytes and in liver tissues of high-fat diet-fed mice. The upregulation of miR-34a resulted in the downregulation of hepatic PPARα and SIRT1 that are the direct targets of miR-34a. Silencing miR-34a led to an initially increased expression of PPARα, SIRT1 and PPARα’s downstream genes. Activation of the central metabolic sensor AMPK was also increased. The miR-34a inhibitor suppressed lipid accumulation and improved the degree of steatosis. Taken together, our data indicated that decreased expression of miR-34a potentially contributes to altered lipid metabolism in NAFLD. Downregulation of miR-34a may be a therapeutic strategy against NAFLD by regulating its target PPARα and SIRT1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672
Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.003 · Cited by 2,799
Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC‐1α
Gerhart‐Hines, Z., Rodgers, J. T., Bare, O., Lerin, C., Kim, S., Mostoslavsky, R., Alt, F. W., Wu, Z., & Puigserver, P. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601633 · Cited by 1,294
MicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status
Hardie, D. G. (2003) · Endocrinology · doi:10.1210/en.2003-0982 · Cited by 994
Reddy, J. K., & Hashimoto, T. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.193 · Cited by 959
Aoyama, T., Peters, J. M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T., & Gonzalez, F. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5678 · Cited by 863
SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase
Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802187200 · Cited by 778
A three-dimensional view of the molecular machinery of RNA interference
Jinek, M., & Doudna, J. A. (2009) · Nature · doi:10.1038/nature07755 · Cited by 744
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression
Cheung, O., Puri, P., Eicken, C., Contos, M. J., Mirshahi, F., Maher, J. W., Kellum, J. M., Min, H., Luketic, V. A., & Sanyal, A. J. (2008) · Hepatology · doi:10.1002/hep.22569 · Cited by 658
Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects
BONNEFONT, J. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.06.004 · Cited by 637
Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease
Cermelli, S., Ruggieri, A., Marrero, J. A., Ioannou, G. N., & Beretta, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023937 · Cited by 564
Sirtuins as potential targets for metabolic syndrome
Guarente, L. (2006) · Nature · doi:10.1038/nature05486 · Cited by 468
Castro, R. E., Ferreira, D. M. S., Afonso, M. B., Borralho, P. M., Machado, M. V., Cortez-Pinto, H., & Rodrigues, C. M. P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.008 · Cited by 350
Yamada, H., Suzuki, K., Ichino, N., Ando, Y., Sawada, A., Osakabe, K., Sugimoto, K., Ohashi, K., Teradaira, R., Inoue, T., et al. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.05.021 · Cited by 327
Wahli, W., Braissant, O., & Desvergne, B. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90045-4 · Cited by 291
Lee, J., Padhye, A., Sharma, A., Song, G., Miao, J., Mo, Y.-Y., Wang, L., & Kemper, J. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.094524 · Cited by 263
Choi, S., Fu, T., Seok, S., Kim, D., Yu, E., Lee, K., Kang, Y., Li, X., Kemper, B., & Kemper, J. K. (2013) · Aging Cell · doi:10.1111/acel.12135 · Cited by 249
Latruffe, N., & Vamecq, J. (1997) · Biochimie · doi:10.1016/s0300-9084(97)81496-4 · Cited by 237
Peroxisome Proliferator-Activated Receptor α Protects against Obesity-Induced Hepatic Inflammation
Stienstra, R., Mandard, S., Patsouris, D., Maass, C., Kersten, S., & Müller, M. (2007) · Endocrinology · doi:10.1210/en.2007-0014 · Cited by 191
Smith, J. J., Kenney, R. D., Gagne, D. J., Frushour, B. P., Ladd, W., Galonek, H. L., Israelian, K., Song, J., Razvadauskaite, G., Lynch, A. V., et al. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-31 · Cited by 186
Pogribny, I. P., Starlard-Davenport, A., Tryndyak, V. P., Han, T., Ross, S. A., Rusyn, I., & Beland, F. A. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.113 · Cited by 185
Differential expression of microRNAs in mouse liver under aberrant energy metabolic status
Li, S., Chen, X., Zhang, H., Liang, X., Xiang, Y., Yu, C., Zen, K., Li, Y., & Zhang, C.-Y. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800509-jlr200 · Cited by 184
Self-citationEpigenetic Regulation of miR-34a Expression in Alcoholic Liver Injury
Meng, F., Glaser, S. S., Francis, H., Yang, F., Han, Y., Stokes, A., Staloch, D. A., McCarra, J., Liu, J., Venter, J. K., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.010 · Cited by 144
Dang, Y., Luo, D., Rong, M., & Chen, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061054 · Cited by 121
Controlling SIRT1 expression by microRNAs in health and metabolic disease
Lee, J., & Kemper, J. K. (2010) · Aging · doi:10.18632/aging.100184 · Cited by 112
Li, W., Chen, C., Xu, M., Guo, J., Li, Y., Xia, Q., Liu, H., He, J., Yu, H., & Zhu, L. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08075.x · Cited by 111
Self-citationKerr, T. A., Korenblat, K., & Davidson, N. O. (2011) · Translational research · doi:10.1016/j.trsl.2011.01.008 · Cited by 106
Tryndyak, V., Latendresse, J. R., Montgomery, B. A., Ross, S. A., Beland, F. A., Rusyn, I., & Pogribny, I. P. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.04.018 · Cited by 106
Current therapeutic strategies in non‐alcoholic fatty liver disease
Dowman, J. K., Armstrong, M. J., Tomlinson, J., & Newsome, P. N. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01403.x · Cited by 100
AMP-activated protein kinase and the metabolic syndrome
Fryer, L. G., & Carling, D. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330362 · Cited by 93
microRNAs: Fad or future of liver disease
Lakner, A. M. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i20.2536 · Cited by 85
Effects of MicroRNAs on Fucosyltransferase 8 (FUT8) Expression in Hepatocarcinoma Cells
Bernardi, C., Soffientini, U., Piacente, F., & Tonetti, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076540 · Cited by 74
Dual Role of MicroRNAs in NAFLD
Ceccarelli, S., Panera, N., Gnani, D., & Nobili, V. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048437 · Cited by 73
Nakajima, T., Tanaka, N., Kanbe, H., Hara, A., Kamijo, Y., Zhang, X., Gonzalez, F. J., & Aoyama, T. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.052928 · Cited by 71
Lenz, L., Marx, J., Chamulitrat, W., Kaiser, I., Gröne, H., Liebisch, G., Schmitz, G., Elsing, C., Straub, B. K., Füllekrug, J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.226530 · Cited by 52
Chiu, L.-Y., Kishnani, P. S., Chuang, T., Tang, C., Liu, C., Bali, D. S., Koeberl, D. D., Austin, S. L., Boyette, K., Weinstein, D. A., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0890-2 · Cited by 49
Dongiovanni, P., & Valenti, L. V. C. (2013) · PPAR Research · doi:10.1155/2013/452061 · Cited by 27
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615
NAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 405
MicroRNA-mediated regulation of glucose and lipid metabolism
Agbu, P., & Carthew, R. W. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00354-w · Cited by 363
Lee, Y.-S., Kim, S. Y., Ko, E., Lee, J.-H., Yi, H.-S., Yoo, Y. J., Je, J., Suh, S. J., Jung, Y. K., Kim, J. H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03389-2 · Cited by 233
Metadata
- Authors
- Ding, J., Li, M., Wan, X., Jin, X., Chen, S., Yu, C., & Li, Y.
- Venue
- Scientific Reports
- Published
- 2015-09-02
- Volume
- 5
- Issue
- 1
- Pages
- 13729-13729
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2404854535
- Cited by
- 261
- References
- 38
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.